Cambridge Analytica scandal still lingering on as Meta settles with Australian users
| ALT Stock | USD 8.25 0.07 0.86% |
Slightly above 51% of Altimmune's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Altimmune suggests that some traders are interested. Altimmune's investing sentiment can be driven by a variety of factors including economic data, Altimmune's earnings reports, geopolitical events, and overall market trends.
Altimmune |
The stench of Cambridge Analytica is still lingering around Facebook, as parent Meta just agreed to pay Australian users AUD 50 million over the scandal.
Read at engadget.com
 |
Altimmune Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Altimmune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Altimmune Fundamental Analysis
We analyze Altimmune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Altimmune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Altimmune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Earning
Price To Earning Comparative Analysis
Altimmune is currently under evaluation in price to earning category among its peers. Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.
Altimmune Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Altimmune stock to make a market-neutral strategy. Peer analysis of Altimmune could also be used in its relative valuation, which is a method of valuing Altimmune by comparing valuation metrics with similar companies.
Peers
Altimmune Related Equities
| CGTX | Cognition Therapeutics | 8.62 | ||||
| INZY | Inozyme Pharma | 6.41 | ||||
| ATHA | Athira Pharma | 5.45 | ||||
| MDGL | Madrigal Pharmaceuticals | 5.12 | ||||
| AKRO | Akero Therapeutics | 3.31 | ||||
| CABA | Cabaletta Bio | 3.03 | ||||
| ARDX | Ardelyx | 2.77 | ||||
| DAWN | Day One | 2.65 | ||||
| SAVA | Cassava Sciences | 2.62 | ||||
| AVXL | Anavex Life | 1.89 | ||||
| VKTX | Viking Therapeutics | 1.83 | ||||
| ACAD | ACADIA Pharmaceuticals | 0.84 | ||||
| INMB | INmune Bio | 0.45 | ||||
| FBIO | Fortress Biotech | 1.15 | ||||
| ZURA | Zura Bio | 2.56 | ||||
| TERN | Terns Pharmaceuticals | 3.14 | ||||
| XFOR | X4 Pharmaceuticals | 4.69 | ||||
| HOOK | Hookipa Pharma | 5.61 | ||||
| VSTM | Verastem | 5.63 | ||||
| HEPA | Hepion Pharmaceuticals | 7.55 | ||||
| BIVI | Biovie | 8.65 | ||||
| RVPH | Reviva Pharmaceuticals | 10.67 |
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.